CERo Therapeutics Holdings (CERo Therapeutics Holdings) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

CERo Therapeutics Holdings's net issuance of preferred for the six months ended in Dec. 2022 was $0.00 Mil. The number is 0, which means that CERo Therapeutics Holdings has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

CERo Therapeutics Holdings's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

CERo Therapeutics Holdings Net Issuance of Preferred Stock Historical Data

The historical data trend for CERo Therapeutics Holdings's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Net Issuance of Preferred Stock Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Net Issuance of Preferred Stock

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Net Issuance of Preferred Stock	-	-

CERo Therapeutics Holdings Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

CERo Therapeutics Holdings Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024